India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
Select options
This product has multiple variants. The options may be chosen on the product page
Details
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The debut episode of NAR’s Change Agents podcast highlights why real estate expertise is more valuable than ever in an AI-driven world. eXp Realty CEO Leo Pareja explains that while technology accelerates communication and connections, consumers still rely on seasoned professionals to guide them through life’s biggest financial decisions. From the Everest analogy to real-world AI success stories, the conversation reveals how trust, transparency, and expert guidance remain the core of the real estate experience.
U.S. 30‑year mortgage rates have dipped to 5.98%, breaking below 6% for the first time since 2022. This third consecutive weekly decline signals a potentially energized spring buying season as lower Treasury yields and easing market anxiety push rates down. Buyers, sellers, and real estate professionals may see renewed activity as affordability slightly improves and refinancing picks up momentum.
A sweeping federal reporting requirement is about to impact how companies, trusts, investors, and even cash buyers purchase residential real estate. FinCEN’s new rule closes long‑standing loopholes that allowed anonymous all‑cash property deals, requiring many entity-based buyers to disclose their true beneficial owners. Real estate agents, brokers, and advisors should brace for workflow changes and increased compliance responsibilities, while investors are urged to review their acquisition structures now to avoid delays once the rule takes effect.
After briefly dipping below 6 percent for the first time in years, mortgage rates have surged again following U.S.-Israeli military strikes on Iran. Rising oil prices and a jump in Treasury yields have pushed the average 30-year fixed rate back to 6.12 percent, creating fresh uncertainty just as the spring housing market was gaining traction. Experts warn that continued geopolitical instability could keep rates elevated, while upcoming U.S. employment data may determine whether relief is on the horizon for buyers and sellers.
New 2026 data reveals that the average life insurance policy costs just 26 dollars a month—less than most lunch outings—making it more affordable than many professionals expect. Rates vary based on age, health, gender, smoking habits, and term length, with younger and healthier applicants paying significantly less. As real estate, mortgage, insurance, and finance professionals plan long-term financial stability, understanding these pricing factors is crucial.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
